Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 21Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 4Triple Negative Breast Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Patient Preference 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1

Interventions

Cyclophosphamide 45fludarabine phosphate 39Peripheral Blood Stem Cell Transplantation 35Busulfan 34Antilymphocyte Serum 26Tacrolimus 25Cyclosporine 25Methotrexate 23Filgrastim 23Mycophenolic Acid 22Radiotherapy 21Melphalan 17Etoposide 15Cytarabine 15Whole-Body Irradiation 14Methylprednisolone 13Cord Blood Stem Cell Transplantation 12Azacitidine 9Specimen Handling 8Biopsy 8ruxolitinib 7Sirolimus 7Cyclosporins 7Alemtuzumab 7Thiotepa 6Decitabine 6sargramostim 5Rituximab 5fludarabine 4Tretinoin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic-Myeloproliferative Diseases × decitabine and cedazuridine drug combination × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡